News

Many people with advanced Parkinson’s disease may actually not have widespread accumulation of toxic protein clumps known as Lewy bodies, which have long been thought to accompany the neurological condition in its later stages, according to a new study from U.S. researchers. The scientists found that most…

A growing body of research suggests that the gut microbiome — the community of bacteria and other microscopic organisms that live in the human digestive tract — may play key roles in the development and progression of Parkinson’s disease. Data suggest that it may be possible to develop Parkinson’s…

The U.S. Food and Drug Administration (FDA) has given Gain Therapeutics a green light to launch a clinical trial — to run across three continents — testing GT-02287, an oral therapy designed to prevent the formation of toxic protein clumps in Parkinson’s disease. The agency clearance follows positive early…

Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease patients with sasineprocel (ANPD001). For the first time in the study, these participants received a new, commercial-ready formulation of the cell therapy designed to make future manufacturing and treatment…

A European Medicines Agency (EMA) committee is recommending approval of Hopledo (IPX203) — an oral extended-release formulation of levodopa and carbidopa sold in the U.S. under the brand name Crexont — for people with Parkinson’s disease in the European Union who experience motor fluctuations despite treatment. The EMA’s…

Parkinson’s advocacy organizations are urging the newly established National Parkinson’s Project Advisory Council to move quickly to implement the project, a U.S. strategy to prevent, diagnose, treat, and ultimately cure Parkinson’s disease. The American Parkinson Disease Association (APDA), The Michael J. Fox Foundation for Parkinson’s Research (MJFF),…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has granted $2.74 million to X-tosis to support the preclinical development of XTS001, the company’s lead candidate for the treatment of Parkinson’s disease. The funding, granted through MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, will support laboratory research…

Clinical trials of UX-DA003, an experimental stem cell therapy for Parkinson’s disease developed by Unixell Biotechnology, can now begin in the U.S. following clearance from the Food and Drug Administration (FDA). The therapy aims to replace dopaminergic neurons, which are the nerve cells lost in Parkinson’s. It uses…

A new personalized, adaptive deep brain stimulation (aDBS) system developed by researchers at the University of California, San Francisco (UCSF) helped improve gait and reduce falls in a small clinical trial involving people with Parkinson’s disease. By detecting neural signals and…

A $2.5 million research grant from The Michael J. Fox Foundation (MJFF) will help expand a Phase 2 clinical study testing the experimental treatment NEU-411 in people with early Parkinson’s disease. Neuron23 will use the funds to activate four clinical sites in Israel for the Phase…